Technologieangebote

Humyd® ist ein leicht handhabbares und gut zu transportierendes Präparat zur Verbesserung der wesentlichen Bodeneigenschaften, welches in der Regel in pelletierter Form angewandt wird.

Die Implantationstechnologie ermöglicht die Herstellung von photokatalytisch wirksamem TiO2 in Titan- oder Titanlegierungsoberflächen.

Wissenschaftler der Universität Göttingen haben neue hochaktive Wirkstoffe sowie deren Anbindung an tumorspezifische Antikörper für die gezielte Tumortherapie (ADC) entwickelt. Die Umwandlung dieser spaltbaren Antikörper-Wirkstoff-Konjugate zu hochtoxischen Substanzen erfolgt dabei erst in der Tumorzelle.

Pain is probably the most common symptom and sensation of a disease, and a big individual and socioeconomic challenge. Diagnostic tools are limited and do not result in clear mechanism-based insight into the etiology of the individual pain. PET-tracers are widely used as diagnostic and therapeutic tools in several types of cancer, besides other applications of visualization in various medical indications. However, there are so far only few reports, which utilize PET-tracer and PET-scan for the detection of pain (see references). The inventors have provided proof that an established PET-tracer for use in cancer can be also utilized for the detection of pain as a second medical application. They found this tracer to be enriched at the peripheral site of pain (see figure). The amount of tracer-enrichment strongly correlated with the measured change in pain sensitivity. On behalf of the University of Cologne and of the Witten/Herdecke University, PROvendis offers access to rights for commercial use as well as the opportunity for further co-development and evaluation.

Chronic viral infections are characterized by a reduced responsiveness of T lymphocytes; a process also termed T cell exhaustion. Tumor necrosis factor alpha (TNFalpha) has been shown to be critically involved in this exhaustion process. Consequently, our invention suggests the use of anti-TNFalpha strategies, i.e. either blockade of the TNF-receptor (TNFR) binding side or its enzymatic activity by existing drugs (e.g. Infliximab, Etanercept) for the general treatment of persisting viral infections with the aim to restore T cell function. Proof for the success of this approach has been delivered by the LCMV mouse model and the in vitro treatment of HIV patients, and is in addition supported by results from studies in systems biology. On behalf of University of Bonn and University of Cologne, we are offering this opportunity for licensing. In case of interest we will be pleased to inform you about the patent status.

The increasing trend towards lightweight constructions, especially in the aerospace sector and in automotive production requires the use of new technologies, manufacturing processes and materials. FRP in particular, are frequently used in this context, due to their high stiffness and strength. The invention proposes a reliable method to weld FRP components onto other FRP components or onto metallic structures. This becomes possible by inserting metallic inserts into the composite, that serve as bridging points to enable a resistance projection welding process. A patent application has been filed in Germany. On behalf of the RWTH University, PROvendis is seeking a partner for further development in view of funding and licensing the technology.